Trial Profile
Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Jan 2024
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; Diphtheria tetanus and pertussis vaccine; Haemophilus vaccines; Hepatitis B vaccine; Measles mumps and rubella virus vaccine; Pneumococcal vaccine; Poliovirus vaccine inactivated; Rotavirus vaccine; Varicella vaccines
- Indications Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections
- Focus Pharmacodynamics; Registrational
- Sponsors Sanofi Pasteur
- 13 Jan 2024 Status changed from recruiting to completed.
- 04 Jan 2023 Planned End Date changed from 27 Oct 2023 to 28 Oct 2024.
- 04 Jan 2023 Planned primary completion date changed from 27 Oct 2023 to 28 Oct 2024.